NLRP3 and inflammatory bowel disease: As a result, targeting its expression and activation by therapeutic modalities such as MSCs treatment [78, 193] or NLRP3-specific inflammasome inhibitors [194, 195] offer an anti-inflammatory milieu and finally protect against IBD.